Primary ciliated muconodular papillary tumor: A rare pulmonary disease and literature review of 65 cases. Issue 12 (7th May 2021)

• Record Type: Journal Article
• Authors: Wang, Yanye; Wang, Dan; Wang, Jun; Zhao, Shikang; Ren, Dian; Chen, Gang; Wang, Qiuhui; Xu, Dongbo; Xu, Song
• Is Part Of: Thoracic cancer. Volume 12:Issue 12(2021)
• Page Start: 1917
• Page End: 1922
• Publication Date: 2021-05-07
• Subjects: bronchiolar adenoma (BA) -- ciliated muconodular papillary tumor (CMPT) -- PD‐L1 -- sequencing -- surgery; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13963
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: A ciliated muconodular papillary tumor (CMPT) or bronchiolar adenoma (BA) is a rather rare and unique type of lung tumor characterized by tripartite cellular components with a papillary‐predominant structure including ciliated columnar cells, mucinous cells, and basal cells. Here, we present the case of a 64‐year‐old woman who was diagnosed with CMPT in our center. In addition to reporting the clinicopathological characteristics of this case, we also conducted whole exome sequencing (WES) to explore the underlying mechanism. According to current evidence, CMPTs tends to be benign or of low grade malignancy. However, this requires further validation. Abstract : A ciliated muconodular papillary tumor (CMPT)/bronchiolar adenoma (BA) is a rare and rather unique type of lung tumor characterized by tripartite cellular components with a papillary‐predominant structure including ciliated columnar cells, mucinous cells, and basal cells. We present the case of a 64‐year‐old woman who was diagnosed with CMPT in our center. In addition to reporting the clinicopathological characteristics of this case, we also conducted whole exome sequencing (WES) to explore the underlying mechanism. According to the current evidence, CMPTs tends to be benign or of low grade malignancy. However, this requires further validation.